Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates

European Journal of Pharmacology

Volumn 451, Issue 2, 2002, Pages 157-160

  Hansard, Matthew J ^a   Smith, Lance A ^a   Jackson, Michael J ^a   Cheetham, Sharon C ^b   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b RenaSci Ltd   (United Kingdom)

Author keywords

Dopamine reuptake inhibition; Dyskinesia; GBR 12909; MPTP treated primate; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE UPTAKE INHIBITOR; LEVODOPA; VANOXERINE;

ANIMAL EXPERIMENT; ARTICLE; CHOREA; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG EFFECT; DRUG MECHANISM; DYSKINESIA; LOCOMOTION; MARMOSET; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CALLITHRIX; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MOTOR ACTIVITY;

EID: 0037072525     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02268-9     Document Type: Article

References (23)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the literature. Mov. Disord. 16:2001;448-458.
2. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. 80:1983;4546-4550.
3. Cass A.W., Zahniser N.R., Flach K.A., Gerhardt G.A. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem. 61:1993;2269-2278.
4. Cheetham S., Butler S., Hearson M., Kerrigan F., Martin K., Needham P., Prow M., Sargent B., Slater N., Skill M., Viggers J., Heal D.J. BTS 74 398: a novel monoamine reuptake inhibitor for the treatment of Parkinson's disease. Br. J. Pharmacol. 123:1998;224.
5. Chiueh C.C., Burns R.S., Markey S.P., Jacobowitz D.M., Kopin I.J. Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci. 36:1985;213-218.
6. Ehringer H., Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen. Wien. Klin. Wochenschr. 38:1960;1236-1239.
7. Gomez-Mancilla B., Bedard P.J. Effect of D-1 and D-2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Ther. 259:1991;409-413.
8. Hansard M.J., Smith L.A., Jackson M.J., Cheetham S.C., Jenner P. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits MPTP-treated primates. J. Pharmacol. Exp. Ther. 2002;. (in press).
9. Heikkila R.E., Manzino L. Behavioural properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur. J. Pharmacol. 103:1984;241-248.
10. Hurtig H.I. Problems with current pharmacologic treatment of Parkinson's disease. Exp. Neurol. 144:1997;10-16.
11. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann. Neurol. 47(Suppl. 1):2000;S90-S104.
12. Jenner P., Rupniak N.M.J., Rose S., Kelly E., Kilpatrick G., Lees A., Marsden C.D. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 50:1984;85-90.
13. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 292:1984;390-394.
14. Lieberman A., Ranhosky A., Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 49:1997;162-168.
15. Marsden C.D. Parkinson's disease. Lancet. 335:1990;948-952.
16. Montastruc J.L., Rascol O., Senard J.M., Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J. Neurol. Neurosurg. Psychiatry. 57:1994;1034-1038.
17. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Lanciego J.L., Artieda J., Gonzola N., Olanow C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Pharmacol. Sci. 23:2000;S8-S19.
18. 1 receptor agonists and dopamine reuptake blockers: new treatment stratagems for Parkinson's disease. Exp. Opin. Ther. Patents. 6:1996;949-953.
19. Pearce R.K.B., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-Phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov. Disord. 10:1995;731-740.
20. Pearce R.K.B., Jackson M., Britton D.R., Shiosaki K., Marsden C.D. Actions of the D-1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-DOPA-primed common marmosets. Psychopharmacology. 142:1999;51-60.
21. Pearce R.K.B., Smith L.A., Jackson M.J., Banerji T., Scheel-Kruger J., Jenner P. The dopamine reuptake inhibitor brasofensine reverses akinesia without dyskinesia in MPTP-treated and L-DOPA-primed common marmosets. Mov. Disord. 2002;. (in press).
22. 2 agonists in squirrel monkeys. Psychopharmacology. 116:1994;9-118.
23. Xu M., Hu X.-T., Cooper D.C., Moratalla R., Graybiel A.M., White F.J., Tonegawa S. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell. 79:1994;945-955.